Literature DB >> 15533952

In the treatment of tuberculosis, you get what you pay for...

Andrew A Vernon, Michael F Iademarco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15533952     DOI： 10.1164/rccm.2409005

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  8 in total

1.  Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Andrew A Vernon; Charles A Peloquin; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2005-09-01       Impact factor: 21.405

2.  Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Authors:  Sang-Won Park; Rokeya Tasneen; Paul J Converse; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Authors:  Ming Zhang; Si-Yang Li; Ian M Rosenthal; Deepak V Almeida; Zahoor Ahmad; Paul J Converse; Charles A Peloquin; Eric L Nuermberger; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2011-02-17       Impact factor: 21.405

4.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 5.  Long term efficacy of DOTS regimens for tuberculosis: systematic review.

Authors:  Helen S Cox; Martha Morrow; Peter W Deutschmann
Journal:  BMJ       Date:  2008-02-04

6.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

7.  Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.

Authors:  Sara H Browne; Anya Umlauf; Amanda J Tucker; Julie Low; Kathleen Moser; Jonathan Gonzalez Garcia; Charles A Peloquin; Terrence Blaschke; Florin Vaida; Constance A Benson
Journal:  PLoS Med       Date:  2019-10-04       Impact factor: 11.069

8.  A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Authors:  Marjorie Z Imperial; Payam Nahid; Patrick P J Phillips; Geraint R Davies; Katherine Fielding; Debra Hanna; David Hermann; Robert S Wallis; John L Johnson; Christian Lienhardt; Rada M Savic
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.